Synaptogenix
Synaptogenix is a clinical-stage biotechnology company focused on developing targeted therapeutics for neurodegenerative diseases and developmental disorders. The company leverages Bryostatin-1 and its analogs, which have shown potential in stimulating synaptic growth factors and preventing neurofibrillary tangles.
Top Regions
https://crunchbase.com/organization/***
https://linkedin.com/company/***
1 past transactions
CannaSoul Analytics
Venture Round in 2023
CannaSoul Analytics is a pioneer in the analysis of cannabis-based products, treatments, and pharmaceuticals, founded by Shmuel Mandel in 2018. The company specializes in the comprehensive analysis of over 100 cannabinoids and 100 terpenes, as well as offering unique endocannabinoid analysis across various matrices. CannaSoul is dedicated to advancing drug discovery through the development of botanical medicine and therapeutics derived from natural compounds. Its services include cannabis molecular analysis, intellectual property licensing, and clinical and pre-clinical trials. Additionally, CannaSoul engages in the screening of cannabis and psilocybin extracts, isolated cannabinoids, and novel molecules using various cell line models, thereby facilitating the integration of botanical medicine into the pharmaceutical industry.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.